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Abstract
Background
The role played by total cholesterol (TC) in risk for subarachnoid hemorrhage (SAH) is
unclear because studies report both high and low TC each as a risk factor. We performed a
systematic review to clarify associations between lipid profile and SAH.
Methods
Our literature search comprised Pubmed, Scopus, and Cochrane Library databases with no
language, publication year, or study type limitations. The Preferred Reporting Items for Sys-
tematic reviews and Meta-analyses (PRISMA) checklist guided our reporting. Data forms
adapted from the Critical Appraisal Skills Program (CASP), and Cochrane Collaboration
guidelines provided a platform for risk-of-bias evaluation. We used a random effects model
to calculate pooled estimates and assessed heterogeneity with I2-statistics.
Results
Of the final 21 studies reviewed, 12 were prospective and 9 retrospective. All studies
assessed TC, four assessed HDL, and none LDL in risk for SAH. Heterogeneity among all,
retrospective, and Asian studies was high (I2 = 79.5%, I2 = 89.0%, and I2 = 84.3%) and con-
siderable in prospective (I2 = 46.0%). We therefore focused on qualitative analysis and
found that only two studies had a low risk of bias. According to these studies high TC
increases risk for SAH in men, whereas the role of HDL remained unclear.
Conclusion
The low-risk-of-bias studies suggest that elevated TC levels elevate risk for SAH in men.
Due to the high prevalence of hypercholesterolemia, population attributable risk (PAR) of
hypercholesterolemia may exceed the PARs of smoking and hypertension in men. Apart
from diabetes and obesity, the risk-factor profile of SAH seems to resemble that of other
cerebrovascular diseases, at least in men.
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Introduction
Epidemiological studies of risk factors of subarachnoid hemorrhage (SAH) are challenging to
conduct for a number of reasons, such as relatively young age at diagnosis, low overall inci-
dence of disease, and high death-rate from the first bleed. The latter implies that outside-hospi-
tal deaths from SAH are comprehensively diagnosed only in countries with a high coverage of
forensic autopsies for sudden deaths. The number of large, long-term, and population-based
prospective studies on risk factors for SAH is limited.[1–3] According to these studies, the
most important risk factors for SAH are smoking, hypertension, female sex, and increasing
age.[1–3]
The role of total cholesterol (TC) in risk for SAH is conflicting, since studies report both
high[3–6] and low[7–12] TC to raise risk. Meta-analyses[13–15] suggest no association
between TC and SAH, whereas they imply that high HDL is protective against SAH. The
reviews do not include, however, a number of studies, such as a recent large study suggesting
that high TC levels (>6.22 mmol/l) associate with future SAH in men.[3] As blood lipid levels
and especially high levels of low-density lipoprotein (LDL) are important risk factors for car-
diovascular diseases in general,[16] we reviewed current evidence on the role of TC and lipo-
proteins as risk factors for SAH. In contrast to the preceding reviews,[13–15] ours also focuses
in depth on methodological quality of the studies reviewed. Readers should note that M.K. and
J.K. have published one of the studies reviewed. [3]
Methods
Literature search
The protocol of this study is available in PROSPERO (International prospective register of sys-
tematic reviews, registration code: CRD42015016347) and follows the Preferred Reporting
Items for Systematic reviews and Meta-analyses for Protocols Statement (PRISMA-P). The
authors J.V.L. and M.K. did all steps of the protocol below; discussion with third-author J.K.
resolved disagreements. We performed the literature search in two parts using Cochrane
Library, Pubmed, and Scopus databases with no language limitations “S1 Methods”. As we
included non-English-language publications, native speakers assisted when necessary. We
included all studies reporting effect estimates with a minimum of two categories for TC, LDL,
HDL, or apolipoprotein concentrations. Depending on the design, we divided all studies into
either prospective or retrospective to facilitate risk-of-bias evaluations. After reviewing risk-of-
bias guidelines from the Cochrane Collaboration Handbook,[17] Critical Appraisal Skills Pro-
gram (CASP),[18] Newcastle-Ottawa scale,[19] and a measurement tool for assessment of mul-
tiple systematic reviews (AMSTAR) [20]we based our risk-of-bias estimations to Cochrane
Collaboration Handbook [17] and CASP [18].
We used the PRISMA checklist[21] as a guide to achieve the accepted standards for report-
ing systematic reviews. Based on the Cochrane Collaborations guidelines,[17] we classified risk
of bias into high, unclear, and low-grade categories. Our review focused especially on measure-
ment bias, selection bias, reporting bias, confounder adjustment, reverse causality, and statisti-
cal power.
Statistical analysis
Based on the Cox proportional hazards model, we estimated sufficient sample size for prospec-
tive follow-up studies. We used a standard significance value of p<0.05, standard power value
of P = 0.8, and incidence value of 20/100 000. For optimistic power analysis, we selected the
hazard ratio (HR) 2.0 (95% CI 1.0–4.0) as effect size with a wide confidence interval and low
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correlation factor value of 0.1 between covariates. We used a random effects model to calculate
pooled estimates and assessed heterogeneity with I2-statistics. For two studies,[7,22] we
inverted the reference category in order to present comparable results. Population attributable
risk (PAR) was calculated with following formula: PAR = pf (RR-1)/[pf (RR-1)+1], where pf is
population fraction with hypercholesterolemia. Stata statistical software version 12.1 Stata
Corp performed all the calculations.
Results
General
Search results. In brief, 21 studies[1–12,22–30] including50 SAH cases emerged that
reported associations between risk for SAH and TC levels “Fig 1”.
Cohort characteristics. Cohort sizes and follow-up times in prospective studies differed
considerably, and the number of SAH ranged from 55[28] to 437[3] (Table 1). In the retrospec-
tive studies, the number of SAHs ranged from 95[5] to 858.[9] The reported mean or median
age at SAH in all studies ranged from 46.9[1] to 64[9] years (Table 1). Supplementary file “S1
Cohorts” describes the data collection in all 12 prospective studies in detail.
Cases. Eight prospective[1–3,6,8,22,29,30] and three[4,5,9] retrospective studies com-
prised both fatal and none-fatal SAHs. Five[1–3,6,29] prospective studies (all Finnish or Nor-
wegian) also reported inclusion of outside hospital deaths (Table 1). Diagnosis-verification
protocol (computed tomography or lumbar puncture) was sufficient in all studies.
Total cholesterol
Associations in prospective studies. Of the 12 studies,[1–3,6–8,22,24,27–30] two[7,8]
suggested that low TC elevated risk for SAH (Table 2). The Swedish study observed, without
having data on smoking, that low TC in men elevated SAH risk with a relative risk (RR) of 3.43
(Table 2).[7] The Japanese hospital-based cohort study reported that high TC lowered SAH
risk with varying RRs 0.2–0.5 in low vs high analysis (no dose-response reported) including
men and women with all their values above 4.14 mmol/l (Table 2).[8]
Two population-based studies,[3,6] including also outside hospital deaths, found that ele-
vated TC levels (>5.59 mmol/l,>6.22 mmol/l, and7.07 mmol/l vs4.92 mmol/l[3] and
7.0 mmol/l vs<5.0 mmol/l[6]) increased risk for SAH in men with an HR of 1.97[3], 1.85[3],
2.18[3], and 1.79[6] (Table 2). The other study also reported dose response as a 1 mmol/l
increase in TC raised risk for SAH in men with an HR of 1.16.[6] The remaining eight prospec-
tive studies[1,2,22,24,27–30] found no associations between TC and SAH (Table 2).
Associations in retrospective studies. Of the nine[4,5,9–12,23,25,26] studies, four[9–12]
found that high TC measured by interview[10,12] or on admission (with hospital-based or
health check-up control group),[9,11] decreased SAH risk with ORs of 0.2 [12], 0.22 [11], 0.41
[10] and (in women only) 0.73 (Table 2).[9]
Three[4,5,25] studies with on-admission measurements found that elevated TC (>4.9[5],
>5.7[4],>6.3[24] mmol/l) elevated risk for SAH (ORs 1.02[5], 2.4[4], 15.7[24]) (Table 2). One
of these studies also found an increased risk for SAH in women with high TC (>5.7 mmol/l)
with an RR of 4.08 (Table 2).[4] Two[4,25] of these three[4,5,25] used mainly healthy controls,
and one[5] used other acute emergency room patients and their on-admission TC values
(Table 2). Two[23,26] studies found no associations between TC and SAH (Table 2).
TC range and power in prospective studies. Nine studies[2,3,6,8,24,27–30] included a
wide range of TC values, but only three[1,3,6] reported a sufficient sample size (31) of male
and female SAHs in the high-TC group to determine an HR under 2 (Tables 2 and 3). Table 2
and “S1 Table” present TC measurement protocols in detail.
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TC measurement and range in retrospective studies. Five[4,5,9,11,25] studies measured
TC on admission after SAH and four[10,12,23,26] by interview. None of the nine[4,5,9–
12,23,25,26] studies included a wide range of TC values in their analysis (Table 2).
Risk-factor adjustments in prospective studies. All[1–3,6,8,22,24,27–30] except one
study[7] recorded known SAH risk factors: age, sex, hypertension, and smoking (or comprised
only smokers or one sex), and all but two[2,7] controlled for them in a multivariable model.
One study reporting high[6] and one low[8] TC as elevating risk for SAH also controlled for
BMI values for confounding in analyses. The two studies reporting low TC as elevating risk
lacked data on smoking[7] or analysis by sex.[8]
Risk-factor adjustments in retrospective studies. All nine[4,5,9–12,23,25,26] studies
recorded known risk factors for SAH, and the four[9–12] reporting low and the three[4,5,25]
high TC as a risk factor for SAH controlled for them all.
Low-TC studies. Five retrospective[4,5,9–11] and three[8,22,27] prospective studies came
from Japan and South Korea, where TC levels are generally lower than in Western countries.
Separate analysis of these studies was still conflicting, since two[4,5] reported high and four[8–
11] low TC as elevating risk, and two[22,27] remained inconclusive (Table 2).
Brief summary of TC findings. Of the 12[1–3,6–8,22,24,27–30] prospective studies, 2
[3,6] found high TC raising risk for SAH in men. Conversely, two prospective studies found
low TC as raising risk for SAH in men[7] and in both men and women[8] while eight
[1,2,22,24,27–30] were indecisive (Table 2). Of the nine[4,5,9–12,23,25,26]retrospective stud-
ies, four[9–12] found low and three[4,5,25] high TC as raising risk for SAH whereas the others
[23,26] remained inconsistent.
Fig 1. PRISMA Flow diagram. Study selection protocol.
doi:10.1371/journal.pone.0152568.g001
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Table 1. Study characteristics. Summary of study characteristics and differences between prospective and retrospective studies.
Authors and
Country
Year Size Age % of
men
Median/mean
Follow-up
SAH
cases
Fatal or non-fatal
SAHs included
Outside-hospital
deaths included
Median/mean
age at SAH
Prospective studies
Finland
Knekt [1] 1991 42
862
20–69 54 12 187 Both Yes 46.9
Korja [3] 2013 64
349
25–74 48.3 17.9 437 Both Yes 59.3
Leppälä [29] 1999 28
519
50–69 100 6 85 Both Yes NR
Zhang [6] 2012 58
235
25–74 47.6 20.1 332 Both Yes NR
Japan
Cui [27] 2007 38
158
40–79 38 10 66 Fatal NR 61.9
Suzuki [8] 2011 156
892
30–89 48.7 3 223 Both No NR
Norway
Sandvei [2] 2012 92
682
20–90+ 33.6 10.9 122 Both Yes 58.9
South Korea
Suh [22] 2001 114
793
35–59 100 6 98 Both No NR
Sweden
Gatchev [7] 1993 54
385
25–74 40.1 20.5 87 Fatal NR NR
USA
Iso [28] * 1989 350
977
35–57 100 6 55 Fatal No 47.4
Neaton [24] *,† 1993 353
340
35–57 100 25 259 Fatal No 47.2
Tirschwell [30] 2004 8 010 30–79 44.2 11 96 Both NR N/A‡
Retrospective
Great Britain &
Denmark
Adamson [25] 1994 189 25–70 44.8 N/A 96 NR No 48
Japan
Inagawa [4] 2005 494 25–96 43.7 N/A 247 Both No 62.6
Inagawa [9] 2010 1 941 31–89 35 N/A 858 Both NR 64
Ohkuma [10] 2003 780 25–85 31 N/A 390 NR No 58
Tokuda [11] 2005 300 24–95 29 N/A 150 NR No 60
Holland
Vlak [12] 2013 824 54.8
(15.8)§
29 N/A 250 Non-fatal No 54.7
Portugal
Canhao [26] 1994 423 <40–65< 30.5 N/A 141 NR NR NR
South Korea
Park [5] 1998 464 II 21–86 48.1 N/A 95 Both NR 51.7
USA
(Continued)
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Subfractions of cholesterol
HDL and other lipoproteins. Three[2,6,29] prospective and one[25] retrospective study
analyzed associations between HDL and risk for SAH (Table 4). The one[25] retrospective also
analyzed association of apolipoprotein B (ApoB) with SAH. None of the studies focused on
any other lipoprotein subtypes, such as LDL, or the lipid subfractions nowadays available with
lipidomic analyses.[31] S1 Table presents a detailed summary of different laboratory methods
that studies used to analyze HDL.
Associations. One prospective study reported that risk for SAH decreased with an HR of
0.6 per SD unit increase in HDL in the subgroup under age 50 when they adjusted for age, sex,
smoking, and alcohol consumption, but not for hypertension (Table 4).[2] Another prospective
study controlled for known risk factors and also excluded participants who were using choles-
terol-lowering medication.[6] After exclusion, however, the association between HDL and
SAH remained unchanged. One study, comprising only male smokers, reported a decreasing
risk for SAH with increasing HDL values (0.84 mmol/l) in their prospective setup (Table 4).
[29] The only retrospective study focusing on lipoprotein subtypes used on-admission mea-
surements, controlled for known risk factors for SAH, and found no significant associations
between HDL, ApoB, and SAH [25] (Table 4).
Risk of bias and power analyses
Prospective studies. Of the 12[1–3,6–8,22,24,27–30] studies, only 2[3,6] had a low risk of
bias; those 2 had a sufficient number of SAHs, included outside hospital sudden deaths, com-
prehensive risk factor control, analysis by sex, wide TC range, unlikely selection bias, sufficient
accuracy (validation) of diagnosis, unlikely measurement bias, and low risk for reverse causality
“Fig 2”. In addition, although one[1] study met these criteria, all participants had very high TC
levels; we thus determined that it had an unclear risk of bias. Nine studies[2,7,8,22,24,27–30]
had a high risk of bias because of limitations in the aforementioned criteria “Fig 2”. Moreover,
power calculations suggested that only three[1,3,6] studies were able to detect significant asso-
ciations between high TC and SAH (Table 3).
Retrospective and low-TC studies. All nine[4,5,9–12,23,25,26] retrospective and eight
[4,5,8–11,22,27] low-TC studies had a high risk of bias because of limitations in the aforemen-
tioned criteria “Fig 2”.
Small studies. Since small studies tend to combine SAH and intracranial hemorrhage in a
group of hemorrhagic stroke, we excluded them from the analysis.
Studies on HDL. Of the four[2,6,25,29] studies, only one[6] had a low risk of bias, because
it met the aforementioned criteria.
Table 1. (Continued)
Authors and
Country
Year Size Age % of
men
Median/mean
Follow-up
SAH
cases
Fatal or non-fatal
SAHs included
Outside-hospital
deaths included
Median/mean
age at SAH
Broderick [23] 2003 930 19–49 39 N/A 312 Non-fatal No NR
*90.1% European. 6.4% African-American. 4.5% Hispanic or Oriental origin
†Includes all SAH deaths through 1999 as additional data
‡ Mean reported only for hemorrhagic stroke category
§ Standard deviation
II 102 intra cranial hemorrhages included in the number
NR = not reported. N/A = not applicable
doi:10.1371/journal.pone.0152568.t001
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Table 2. Associations between TC and SAH. Associations between TC levels and SAH, number of SAHs in the subgroup analyses, and type of TC mea-
surement with control group.
Authors and
country
Lowest vs
highest or vice
versa (mmol/l)
HR/RR/OR
and 95% CIs
No. of
SAHs
among
men
No. of male
cases in
highest
category
No. of SAHs
among
women
No. of female
cases in
highest
category
Cases´ TC measurement
and type of cohort or
control group
Prospective
Finland
Knekt [1] 5.96 vs 6.99< M 0.9 (0.6–
1.5) W 1.0
(0.6–1.8)
102 39 85 39 sB, PB
Korja [3] <4.92 vs 7.07< M 2.18 (1.19–
4.00) W 0.99
(0.62–1.59)
206 58 231 60 sB, PB
Leppälä [29] <4.90 vs 7.00 0.78 (0.38–
1.62)
85 19 - - B, MS
Zhang [6] <5.00 vs 7.00< M 1.79 (1.00–
3.19) W 1.25
(0.71–2.20)
151 49 181 46 sB, PB
Japan
Cui [27] <4.14 vs 7.22 0.60 (0.08–
4.73)
25 NR 41 NR nB, PB
Suzuki [8] <4.14 vs 7.24 0.2 (0.0–0.8) 89 NR 134 NR B, H
Norway
Sandvei [2] 5.9, per SD (1.3) 0.9 (0.7–1.1) 41 NR 81 NR nB, PB
South Korea
Suh [22] § <4.31 vs 5.70< 0.69 (0.37–
1.32)
98 18 - - fB, CP
Sweden
Gatchev [7] § M 5.3 vs 7.6 W
5.4 vs 7.9
M 0.29 (0.10–
0.89) W 0.98
(0.42–2.08)
37 4 50 12 nB, PB
USA
Iso [28] <4.14 vs 7.24 0.16 * 55 1 - - nB, IG
Neaton [24] <4.14 vs 7.24 1.70 (0.76–
3.83)
259 17 - - nB, IG
Tirschwell [30] 4.45 vs 7.50 † 1.3 (0.7–2.4) NR NR NR NR B, HM
Retrospective
Great Britain & Denmark
Adamson [25] <5.40 vs 6.30< 15.7 (2.8–89) 43 NR 53 NR aB, HE
Japan
Inagawa [4] <5.69 vs 5.69< M 2.18 (0.67–
7.08) W 4.08
(1.59–10.46)
108 18 139 48 aB, HE
Inagawa [9] <5.69 vs 5.69< M 0.89 (0.50–
1.60) W 0.73
(0.55–0.98)
276 NR 522 NR aB, HC
Ohkuma [10] NR 0.41 (0.24–
0.71)
119 NR 271 NR I, HE
Tokuda [11] <5.20 vs 5.20< 0.22 (0.12–
0.40)
43 NR 107 NR aB, H
Holland
Vlak [12] NR 0.2 (0.1–0.4) 62 NR 188 NR I, HC
Portugal
(Continued)
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Meta-analysis. In addition to evident methodological differences among studies “Fig 2”,
our meta-analysis showed also considerable heterogeneity. Heterogeneity among retrospective
and Asian studies was high (I2 = 79.5%-89.0%), and considerable in prospective studies (I2 =
46.0%) “Figures A-D in S1 Figures”. Indisputably, meta-analysis on reviewed studies lacks jus-
tification. However, we performed a series of sensitivity analyses and selected the most similar
studies for meta-analysis.
A meta-analysis limited to prospective studies with comparable wide TC groups, major lim-
itations only in an analysis by sex and exclusion of certain SAH types,[3,24,27,30] showed
moderate evidence that high TC elevates SAH risk with an RR of 1.33 “Figure E in S1 Figures”.
Table 2. (Continued)
Authors and
country
Lowest vs
highest or vice
versa (mmol/l)
HR/RR/OR
and 95% CIs
No. of
SAHs
among
men
No. of male
cases in
highest
category
No. of SAHs
among
women
No. of female
cases in
highest
category
Cases´ TC measurement
and type of cohort or
control group
Canhao [26] <6.21 vs 6.21< 0.9 (0.5–1.7) 95 27 46 67 I, HC
Park [5] <3.88 vs 4.9< 1.02 (1.01–
1.02)
24 NR 71 NR aB, A
USA
Broderick [23] NR 0.53 NR NR NR NR I, HE
M = men, W = women, A = acute patients, B = blood sample with no fasting information, aB = blood sample on admission, fB = fasting blood sample,
nB = non-fasting blood sample, sB = semi-fasting blood sample, CP = male civil service and private school workers, H = hospital based, HC = health
check-up, HE = healthy, HM = hypertensive men and menopausal women, I = interview, IG = industry-company workers or government staff, MS = male
smokers, PB = population based, NR = not reported
*Not signiﬁcant and CIs not provided
† Quintile means
§ Reference group inverted in studies of Gatchev and Suh
doi:10.1371/journal.pone.0152568.t002
Table 3. Sample sizes. Required number of person-years and SAHs for subgroup analysis for different HR
values.
HR SAH in subgroup studied Person years needed
1.5 91 452 854
1.6 68 337 026
1.7 53 264 414
1.8 44 215 490
1.9 37 180 715
2.0 31 154 958
2.1 28 135 248
2.2 24 119 760
2.3 22 107 318
2.4 20 97 137
2.5 18 88 675
2.6 17 81 545
2.7 16 75 466
2.8 15 70 229
p<0.05, P = 0.8, covariate correlation factor 0.1, and incidence 20/100 000
doi:10.1371/journal.pone.0152568.t003
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The meta-analysis including only retrospective studies with TC values measured in an acute
phase[9,11,25] showed no association between TC and SAH “Figure F in S1 Figures”. Meta-
analysis including only studies which obtained TC values using interviews[10,12,26] showed
low TC as risk factor (RR 0.42) “Figure G in S1 Figures”. The sensitivity analysis included a
small number of studies, and has unreliable heterogeneity estimates.
Discussion
Some relatively high-quality evidence[3,6] suggests that high TC is a risk factor for SAH in
men questioning the current understanding of SAH epidemiology. The role of HDL remained
unresolved. [6] Only one[25] retrospective study focused on associations between ApoB and
SAH, but found none, whereas none studied LDL. Meta-analyses[13–15] did not find strong
associations between SAH and TC. However, they did not include extensive risk-of-bias analy-
ses and, therefore may have failed to uncover sources of heterogeneity in the studies included.
Internal quality of SAH risk factor studies varies considerably, as most have significant
methodological shortages and gaps in reporting. Five studies[3–6,25] reported high TC, six[7–
12] low TC, and ten others[1,2,22–24,26–30] neither one as increasing risk for SAH. Of all 12
[1–3,6–8,22,24,27–30] prospective studies, 3[1,3,6] had sufficient statistical power to detect
associations between high TC and SAH. Of all 21 studies,[1–12,22–30] only 2[3,6] had a low
risk of bias. According to the classical Hills criteria of causality,[32] the two studies also had
convincing temporality, biological gradient, plausibility, coherence, and analogy. These studies
also included outside hospital SAH deaths. Both originated from the FINNRISK cohort but
from different study groups. The most recent[3] included more SAH cases and found stronger
Table 4. Associations between HDL and SAH. Associations between HDL levels and SAHs, number of SAHs in subgroup analyses and type of HDL mea-
surement with control group.
Authors and
Country
Protective
factor
Highest vs
lowest
(mmol/l)
HR/RR/OR
and 95% CIs
No. of
SAHs
among men
No. of male
cases in lowest
category
No. of SAHs
among
women
No. of female
cases in lowest
category
Cases´ TC measurement
and type of controls or
cohort
Prospective
Finland
Leppälä [29] High HDL 1.45< vs
<0.84
0.26 (0.11–
0.62)
85 14 0 0 B, SM
Zhang [6] None <1.0 vs 1.4< M 0.56 (0.25–
1.25) W 1.27
(0.50–3.28)
151 17 181 15 sB, PB
Norway
Sandvei [2] None 1.4 (SD 0.4) 1.0 (0.9–1.3)* 41 NR 81 NR nB, PB
<50 years High HDL 1.4 (SD 0.4) 0.6 (0.4–0.9)* NR NR NR NR
>50 years Low HDL 1.4 (SD 0.4) 1.2 (1.0–1.5)* NR NR NR NR
Retrospective
Great Britain & Denmark
Adamson
[25]
None 1.4< vs <1.1 NR 43 NR 53 NR aB, HE
ApoB (g/l) None 0.83< vs
<0.65
1.0 CIs NR 43 NR 53 NR
M = men, W = women, B = unknown blood sample, aB = on admission blood sample, nB = non-fasting blood sample, sB = semi-fasting blood sample,
HE = healthy controls, PB = population based cohort, SM = cohort of male smokers, NR = not reported
* per SD increase
doi:10.1371/journal.pone.0152568.t004
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associations between elevated TC and SAH. Also sensitivity analysis including prospective
studies (with comparable TC levels and only few limitations) supported the view that elevated
TC associates with SAH risk. As TC is a well-known risk factor for cardiovascular diseases in
general,[16] and atherosclerotic changes are commonly found in aneurysm walls,[33] the
results for TC seem reasonable. Analysis of low-TC studies separately provided no support for
the hypothesis of a U-shaped risk curve.
The recent low-risk-of-bias study suggested[3] that TC levels over 5.6mmol/l elevate risk of
SAH with HR of approximately 2 in men. Based on the varying prevalence (between 17% and
55%) of hypercholesterolemia worldwide,[34] the HR of 2 in men translates into PAR estimates
ranging from 17% to 35%. The PAR of hypercholesterolemia in men can reach up to 35% in
Europe, and up to 32% in the USA. Because TC levels are increasing in a number of countries,
[35] PAR of hypercholesterolemia is likely to increase especially in developing countries. The
recent low-risk-of-bias study reported HRs of 2.53 and 1.23 for smoking and hypertension in
men. [3] With a prevalence estimate of 25% for smoking and 41% for hypertension, the HRs
translate into PARs of 28% and 9% in men. Thus, TC may significantly contribute to the SAH
incidence among men, and to the difference in risk-factor profiles between sexes.
TC and LDL levels are well-documented risk factors for other cardiovascular diseases
(CVDs), whereas HDL is generally considered a protective risk indicator.[16] The role of a
high LDL is considered to be causal, whereas the causal nature of the HDL association has been
questioned.[36–38] Furthermore, the influence of these factors on CVDs may differ by sex
[39,40] because premenopausal women are also at lower risk for CVDs than are age-matched
men.[16] Physiological changes during menopause elevate risk for CVDs,[41] when TC and
Fig 2. Risk of bias.Classification of risk of bias and sources of bias in all studies.
doi:10.1371/journal.pone.0152568.g002
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LDL levels start to rise at its beginning and reach their peak at approximately age 60.[39] At
the same time, HDL decreases and triglycerides increase, making the lipid profile more unfa-
vorable, thus elevating risk for CVDs, especially in women.[39] Of those included, two[3,8]
prospective studies reporting age-group SAH incidences, further stratified by sex, showed SAH
incidence in women to surpass male incidence at age 65 and above. TC levels often being low
in premenopausal women may in part explain why associations between TC and SAH are diffi-
cult to discover. This emphasizes the importance of analyzing and representing TC associations
by sex and age and indicates that future SAH studies should focus on the role of TC in both
pre- and postmenopausal women separately.
Prospective follow-up studies require a significant number (approx. 270 000) of person-
years and optimally over 35 SAHs for each sex per TC subgroup to reliably study associations
between TC levels and risk for SAH. In addition, because roughly 20% of SAH patients die
away from hospitals or in emergency rooms,[42] and are thus excluded from most studies,
even more person-years may be necessary. Only four[1,3,6,29] Finnish and one Norwegian
[2] population-based studies reported in their analyses inclusion of sudden deaths. Further-
more, TC values should be analyzed as a continuous variable and should include adequate
numbers of participants with TC below 5.0 mmol/l and above 6.5 mmol/l. As the median age
at SAH is nowadays 60 years,[2,3] the study cohort should be of a rather high median age
with a very long follow-up. Even then, reliable studies on TC are nowadays very challenging
to conduct, as a high proportion of those with hypercholesterolemia use statins. A recent ret-
rospective study [43] relying on administrative data suggested that statin use in elderly
patients with unruptured intracranial aneurysms does not affect the incidence rate of SAH.
However, the study did not report TC levels at baseline or after statin treatment, and did not
stratify the results by sex. All these factors considered, it is clear that discovering the epidemi-
ological role of TC in SAH is challenging; relatively small and short-term studies need cau-
tious interpretation.
One of the most important shortcomings in the prospective cohort studies reviewed is their
lack of longitudinal follow-up data; changes in risk-factor profile during the study period may
therefore distort and confound association analyses. For example, in prospective studies from
Norway[2] and Finland,[3,6] TC levels were measured 6 (mean) and 12 (median) years before
SAH. As TC values have been a target of intensive drug and diet therapies during recent
decades,[16] it is likely that baseline values had changed during follow-ups. Indeed, since the
1970s, when the study surveys began, the decline in TC of the Finnish population has been
rapid, [44] and thus the risk estimates for TC levels may be unreliable. However, these modifi-
cations can only underestimate the role of high TC levels as a risk factor for SAH, making any
associations between TC and SAH only decrease or disappear.
The reliability of retrospective studies in finding new risk factors for SAH is generally lim-
ited, not only because all outside hospital deaths are excluded from analyses, but also because
of the evident risk of measurement bias when risk factors are measured by interview or after
SAH. This was also evident in our sensitivity analyses, which included only on admission TC
measurements or measurements by interview. Studies which measured TC by interview sug-
gested that low TC elevates SAH risk. As TC levels may decrease during and after SAH,[45,46]
all studies which measure TC on admission or within days after SAH are prone to reverse cau-
sality. This view is consistent with the results of the retrospective study[9] reporting TC as a
risk factor for aneurysm formation but not for SAH. In addition, selection bias may weaken the
generalizability of hospital-based studies by limiting the inclusion of patients with low TC in
their control groups. Indeed, those retrospective studies[4,5,25] that reported high TC as lead-
ing to increased risk for SAH, used other emergency room patients or healthy people as control
groups.
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Our review has a few shortcomings. First, we may have missed some relevant publications
due to indexing errors and limitations in the search strategy. Our search strategy, however,
yielded 21 reviewed studies whereas the three earlier systematic reviews on this topic com-
prised only 7,[15] 6,[13] and 3[14] studies with over 50 SAH cases. Second, the review includes
study by two authors (M.K. and J.K.), making it possible that unintentional conflict of interest
has biased risk-of-bias estimations. We tried to avoid this with an established and public study
protocol registered in the PROSPERO. Despite this, readers need to take this into consideration
when evaluating the presented evidence. Third, a reliable meta-analysis, one which could have
elucidated the role of TC in SAH, was impossible due to methodological differences and lack of
the necessary additional data.
Conclusion
Elevated TC levels may elevate risk for SAH among men, and therefore lipid profile should per-
haps be taken into account when assessing risk for SAH in men. No convincing evidence exist
that low TC elevates risk for SAH. Apart from diabetes and obesity, the risk-factor profile of
SAH resembles that of other CVDs, at least in men.
Supporting Information
S1 Cohorts. Description of cohorts used in prospective studies.
(DOCX)
S1 Figures. Meta-analysis and sensitivity analyses.
(DOCX)
S1 Methods. Search strategy and protocol.
(DOCX)
S1 PRISMA Checklist.
(DOC)
S1 Table. Cholesterol measurement protocols used in studies reviewed.
(DOCX)
Acknowledgments
We appreciate James Neaton and Marie Sandvei´s providing additional information about
their studies. We thank Jari Haukka and Marja-Liisa Lindbohm for critical revisions and Tiina
Heino for advice in search protocol, and Carolyn Brimley Norris for language revision. We
also thank Liang He, Teemu Hermunen, Joonas Kirsi, and Siamak Bidel for translations.
Author Contributions
Conceived and designed the experiments: JVL JK MK. Performed the experiments: JVL JK
MK. Analyzed the data: JVL JK MK. Contributed reagents/materials/analysis tools: JVL JK
MK. Wrote the paper: JVL JK MK. Did the literature search and the data collection: JVL MK.
References
1. Knekt P, Reunanen A, Aho K, Heliovaara M, Rissanen A, Aromaa A, et al. Risk factors for subarachnoid
hemorrhage in a longitudinal population study. J Clin Epidemiol 1991; 44(9):933–939. PMID: 1890435
2. Sandvei MS, Lindekleiv H, Romundstad PR, Muller TB, Vatten LJ, Ingebrigtsen T, et al. Risk factors for
aneurysmal subarachnoid hemorrhage—BMI and serum lipids: 11-year follow-up of the HUNT and the
Cholesterol and Subarachnoid Hemorrhage
PLOS ONE | DOI:10.1371/journal.pone.0152568 April 14, 2016 12 / 15
Tromso Study in Norway. Acta Neurol Scand 2012 Jun; 125(6):382–388. doi: 10.1111/j.1600-0404.
2011.01578.x PMID: 21793808
3. Korja M, Silventoinen K, Laatikainen T, Jousilahti P, Salomaa V, Hernesniemi J, et al. Risk factors and
their combined effects on the incidence rate of subarachnoid hemorrhage—a population-based cohort
study. PLoS One 2013 Sep 9; 8(9):e73760. doi: 10.1371/journal.pone.0073760 PMID: 24040058
4. Inagawa T. Risk factors for aneurysmal subarachnoid hemorrhage in patients in Izumo City, Japan. J
Neurosurg 2005 Jan; 102(1):60–67. PMID: 15658097
5. Park JK, Kim HJ, Chang SJ, Koh SB, Koh SY. Risk factors for hemorrhagic stroke in Wonju, Korea.
Yonsei Med J 1998 Jun; 39(3):229–235. PMID: 9664827
6. Zhang Y, Tuomilehto J, Jousilahti P, Wang Y, Antikainen R, Hu G. Total and high-density lipoprotein
cholesterol and stroke risk. Stroke 2012 Jul; 43(7):1768–1774. doi: 10.1161/STROKEAHA.111.646778
PMID: 22496337
7. Gatchev O, Rastam L, Lindberg G, Gullberg B, Eklund GA, Isacsson SO. Subarachnoid hemorrhage,
cerebral hemorrhage, and serum cholesterol concentration in men and women. Ann Epidemiol 1993
Jul; 3(4):403–409. PMID: 8275217
8. Suzuki K, Izumi M, Sakamoto T, Hayashi M. Blood pressure and total cholesterol level are critical risks
especially for hemorrhagic stroke in Akita, Japan. Cerebrovasc Dis 2011; 31(1):100–106. doi: 10.1159/
000321506 PMID: 21079399
9. Inagawa T. Risk factors for the formation and rupture of intracranial saccular aneurysms in Shimane,
Japan. World Neurosurg 2010 Mar; 73(3):155–64; discussion e23. doi: 10.1016/j.surneu.2009.03.007
PMID: 20860953
10. Ohkuma H, Tabata H, Suzuki S, Islam MS. Risk factors for aneurysmal subarachnoid hemorrhage in
Aomori, Japan. Stroke 2003 Jan; 34(1):96–100. PMID: 12511757
11. Tokuda Y, Stein GH. Serum lipids as protective factors for subarachnoid hemorrhage. J Clin Neurosci
2005 Jun; 12(5):538–541. PMID: 15975790
12. Vlak MH, Rinkel GJ, Greebe P, Greving JP, Algra A. Lifetime risks for aneurysmal subarachnoid haem-
orrhage: multivariable risk stratification. J Neurol Neurosurg Psychiatry 2013 Jun; 84(6):619–623. doi:
10.1136/jnnp-2012-303783 PMID: 23355806
13. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J, et al. Risk factors for subarachnoid
hemorrhage: an updated systematic review of epidemiological studies. Stroke 2005 Dec; 36(12):2773–
2780. PMID: 16282541
14. Teunissen LL, Rinkel GJ, Algra A, van Gijn J. Risk factors for subarachnoid hemorrhage: a systematic
review. Stroke 1996 Mar; 27(3):544–549. PMID: 8610327
15. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol Levels and Risk of Hemorrhagic Stroke: A Sys-
tematic Review and Meta-Analysis. Stroke 2013 May 23.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treat-
ment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cho-
lesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17;106
(25):3143–3421.
17. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version
5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-
handbook.org. Version 5.0.2 ed.; 2009.
18. Critical Appraisal Skills Programme (CASP). CASP Checklists (http://media.wix.com/ugd/dded87_
e37a4ab637fe46a0869f9f977dacf134.pdf) Oxford CASP 2014.
19. Newcastle-Ottawa Scale (NOS). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
20. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a
measurement tool to assess the methodological quality of systematic reviews. BMCMed Res Methodol
2007 Feb 15; 7:10. PMID: 17302989
21. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMAGroup. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. PLoS Med 2009 Jul 21; 6(7):e1000097. doi: 10.
1371/journal.pmed.1000097 PMID: 19621072
22. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cholesterol and haemorrhagic stroke in
men: Korea Medical Insurance Corporation Study. Lancet 2001 Mar 24; 357(9260):922–925. PMID:
11289349
23. Broderick JP, Viscoli CM, Brott T, KernanWN, Brass LM, Feldmann E, et al. Major risk factors for aneu-
rysmal subarachnoid hemorrhage in the young are modifiable. Stroke 2003 Jun; 34(6):1375–1381.
PMID: 12764233
Cholesterol and Subarachnoid Hemorrhage
PLOS ONE | DOI:10.1371/journal.pone.0152568 April 14, 2016 13 / 15
24. Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L. Risk factors for death from different types of
stroke. Multiple Risk Factor Intervention Trial Research Group. Ann Epidemiol 1993 Sep; 3(5):493–
499. PMID: 8167825
25. Adamson J, Humphries SE, Ostergaard JR, Voldby B, Richards P, Powell JT. Are cerebral aneurysms
atherosclerotic? Stroke 1994 May; 25(5):963–966. PMID: 8165691
26. Canhao P, Pinto AN, Ferro H, Ferro JM. Smoking and aneurysmal subarachnoid haemorrhage: a case-
control study. J Cardiovasc Risk 1994 Aug; 1(2):155–158. PMID: 7606628
27. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, et al. Serum total cholesterol levels and
risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis
2007 Oct; 194(2):415–420. PMID: 16970954
28. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mor-
tality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med
1989 Apr 6; 320(14):904–910. PMID: 2619783
29. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke
subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999 Dec; 30(12):2535–
2540. PMID: 10582974
30. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, LongstrethWT Jr, Psaty BM. Association of cho-
lesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004 Nov 23; 63
(10):1868–1875. PMID: 15557504
31. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikainen LP, et al. Genome-wide
association study identifies multiple loci influencing human serummetabolite levels. Nat Genet 2012
Jan 29; 44(3):269–276. doi: 10.1038/ng.1073 PMID: 22286219
32. Hill AB. The Environment and Disease: Association Or Causation? Proc R Soc Med 1965 May;
58:295–300. PMID: 14283879
33. Frosen J, Tulamo R, Paetau A, Laaksamo E, Korja M, Laakso A, et al. Saccular intracranial aneurysm:
pathology and mechanisms. Acta Neuropathol 2012 Jun; 123(6):773–786. doi: 10.1007/s00401-011-
0939-3 PMID: 22249619
34. World Health Organization. Description of the global burden of NCDs, their risk factors and determi-
nants. Global status report on noncommunicable diseases 201 April 2011:1–176.
35. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional,
and global trends in serum total cholesterol since 1980: systematic analysis of health examination sur-
veys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011 Feb
12; 377(9765):578–586. doi: 10.1016/S0140-6736(10)62038-7 PMID: 21295847
36. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT,
HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cho-
lesterol in 54,500 individuals. J Clin Endocrinol Metab 2012 Feb; 97(2):E248–56. doi: 10.1210/jc.2011-
1846 PMID: 22090275
37. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian random-
ization of blood lipids for coronary heart disease. Eur Heart J 2015 Mar 1; 36(9):539–550. doi: 10.1093/
eurheartj/eht571 PMID: 24474739
38. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma
HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012 Aug
11; 380(9841):572–580. doi: 10.1016/S0140-6736(12)60312-2 PMID: 22607825
39. Evangelista O, McLaughlin MA. Review of cardiovascular risk factors in women. Gend Med 2009; 6
Suppl 1:17–36. doi: 10.1016/j.genm.2009.02.004 PMID: 19318217
40. Tan YY, Gast GC, van der Schouw YT. Gender differences in risk factors for coronary heart disease.
Maturitas 2010 Feb; 65(2):149–160. doi: 10.1016/j.maturitas.2009.09.023 PMID: 19897327
41. Auro K, Joensuu A, Fischer K, Kettunen J, Salo P, Mattsson H, et al. A metabolic view on menopause
and ageing. Nat Commun 2014 Aug 21; 5:4708. doi: 10.1038/ncomms5708 PMID: 25144627
42. Korja M, Silventoinen K, Laatikainen T, Jousilahti P, Salomaa V, Kaprio J. Cause-specific mortality of 1-
year survivors of subarachnoid hemorrhage. Neurology 2013 Jan 29; 80(5):481–486. doi: 10.1212/
WNL.0b013e31827f0fb5 PMID: 23303843
43. Bekelis K, Smith J, ZhouW, MacKenzie TA, Roberts DW, Skinner J, et al. Statins and subarachnoid
hemorrhage in Medicare patients with unruptured cerebral aneurysms. Int J Stroke 2015 Oct; 10 Suppl
A100:38–45. doi: 10.1111/ijs.12559 PMID: 26120925
44. Borodulin K, Vartiainen E, Peltonen M, Jousilahti P, Juolevi A, Laatikainen T, et al. Forty-year trends in
cardiovascular risk factors in Finland. Eur J Public Health 2015 Jun; 25(3):539–546. doi: 10.1093/
eurpub/cku174 PMID: 25422363
Cholesterol and Subarachnoid Hemorrhage
PLOS ONE | DOI:10.1371/journal.pone.0152568 April 14, 2016 14 / 15
45. Aull S, LalouschekW, Schnider P, Sinzinger H, Uhl F, Zeiler K. Dynamic changes of plasma lipids and
lipoproteins in patients after transient ischemic attack or minor stroke. Am J Med 1996 Sep; 101
(3):291–298. PMID: 8873491
46. Woo J, Lam CW, Kay R, Wong HY, Teoh R, Nicholls MG. Acute and long-term changes in serum lipids
after acute stroke. Stroke 1990 Oct; 21(10):1407–1411. PMID: 2219204
Cholesterol and Subarachnoid Hemorrhage
PLOS ONE | DOI:10.1371/journal.pone.0152568 April 14, 2016 15 / 15
